PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated…
PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors • 48% confirmed overall response rate (ORR) with a 10.4-month median duration of response
- Product
- rezatapopt
- Milestone
- topline data
- Indication
- platinum-resistant/refractory ovarian cancer
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The 8-K provides updated investigator-assessed efficacy for the pivotal Phase 2 portion, including ORR and duration in platinum-resistant/refractory ovarian cancer, and reiterates an NDA submission plan for accelerated approval in 1Q 2027.
Market read
Traders can update biotech risk models immediately using the newly disclosed ORR/duration figures and the stated 1Q 2027 NDA timeline.
What to watch
Safety tolerability in a larger, registrational context and the strength of the FDA accelerated-approval package (including confirmatory strategy) could be the gating items despite the positive ORR.
Background
PMV Pharma’s rezatapopt is a p53 Y220C reactivator in the PYNNACLE Phase 1/2 trial, with Phase 2 designed as a registrational expansion basket across multiple tumor cohorts.
Ticker impact
PMV Pharmaceuticals filed an 8-K with updated PYNNACLE Phase 2 results for rezatapopt, including 48% ORR and planned NDA submission in 1Q 2027.
Likely upward pressure as traders price in higher odds of accelerated approval and near-term NDA filing execution.
The filing discloses new, specific efficacy endpoints (ORR, duration, disease control) plus a concrete first-quarter 2027 NDA plan, which are direct decision inputs for biotech risk/reward.
Market effects
Strengthens sentiment for p53 Y220C targeted oncology and small-molecule reactivators, potentially improving read-through for similar precision oncology programs.
Primarily US biotech sentiment, with conference presentation in Europe adding incremental visibility.
Moderate global relevance via ENA 2026 late-breaking presentation and regulatory pathway expectations.
Counterpoint
Single-arm basket data can overstate durability and generalizability; investors may discount ORR without randomized confirmation and longer follow-up.
Key entities
- companyPMV Pharmaceuticals, Inc.
Nasdaq-listed precision oncology company reporting updated PYNNACLE Phase 2 data for rezatapopt.
- drugRezatapopt (PC14586)
Small-molecule p53 reactivator targeting the TP53 Y220C mutation.
- clinical_trialPYNNACLE Phase 2
Registrational single-arm expansion basket trial with ovarian, lung, breast, endometrial, and other solid tumor cohorts.
- conferenceENA 2026
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics where the data were presented as a late-breaking oral.
